4.18
-0.02 (-0.36%)
| Previous Close | 4.19 |
| Volume | 576,845 |
| Price / Book | 0.590 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -6.04 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 8.29% |
| Current Ratio (MRQ) | 13.93 |
| Operating Cash Flow (TTM) | -59.79 M |
| Levered Free Cash Flow (TTM) | -36.41 M |
| Return on Assets (TTM) | -33.29% |
| Return on Equity (TTM) | -68.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Artiva Biotherapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.7 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.84 |
Select this tab to load the latest available analysis.
|
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.99% |
| % Held by Institutions | 89.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ra Capital Management, L.P. | 30 Jun 2026 | 17,955,642 |
| Viking Global Investors Lp | 30 Jun 2026 | 2,604,166 |
| Blackstone Inc. | 30 Jun 2026 | 2,403,437 |
| 5Am Venture Management, Llc | 30 Jun 2026 | 2,353,304 |
| Venrock Adviser, Llc | 30 Jun 2026 | 2,043,596 |
| Caligan Partners Lp | 30 Jun 2026 | 1,736,111 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 954,861 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 874,542 |
| Propel Bio Management, Llc | 30 Jun 2026 | 696,436 |
| Silverarc Capital Management, Llc | 30 Jun 2026 | 525,000 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |